EUVIMEDEUVIMED entdecken
Crossref

Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery

Johan Sebastian Lopez-Parra, Fatima Hameedat, Sérgio F Sousa iD, Annemiek M E Walenkamp, Flávia Sousa iD, Hélder A Santos iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Johan Sebastian Lopez-Parra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomaterials and Biomedical Technology. The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (…. Hauptthemen laut MEDLINE: Glioblastoma, Drug Resistance, Neoplasm, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit nennt 102 Literaturangaben. Gefördert von: HORIZON EUROPE European Innovation Council, Universitair Medisch Centrum Groningen, H2020 Marie Sklodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic resistance in glioblastoma (GBM) remains a critical clinical challenge. To better understand its molecular basis, we performed a multistage computational analysis on a resistant GBM data set derived from the Ivy Glioblastoma Atlas Project, filtered for unmethylated MGMT and EGFR amplification. A subtype-specificity analysis identified distinct expression patterns for established biomarkers, including PDGFRA, FAP, and CD163, providing refined context for their roles in specific GBM subtypes. Kaplan-Meier analysis confirmed that high PDGFRA expression correlates with poor survival in this resistant population. To explore its therapeutic tractability, we developed a Quantitative Structure-Activity Relationship (QSAR) model targeting PDGFRA. This led to the in silico identification of a novel lead compound with a distinct thiazolopyridine-based scaffold and high predicted potency. Our findings demonstrate how integrated bioinformatic pipelines can dissect the complex landscape of GBM resistance, contextualize the roles of key oncogenes, and guide the rational design of potential new inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaDrug Resistance, NeoplasmBiomarkers, TumorBrain NeoplasmsHumansDrug DiscoveryQuantitative Structure-Activity RelationshipComputational BiologyReceptor, Platelet-Derived Growth Factor alphaAntineoplastic AgentsErbB Receptors

Stichwörter der Autor:innen

bioinformaticsgenomicsglioblastomaglioblastoma resistancetherapeutic biomarkers

Substanzen

Biomarkers, TumorReceptor, Platelet-Derived Growth Factor alphaAntineoplastic AgentsErbB Receptors

Autor:innen und Institutionen

  • Department of Biomaterials and Biomedical Technology. The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen,…
  • Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
  • LAQV/REQUIMTE─BioSIM, Departamento de Biomedicina, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal.
  • Departamento de Engenharia Química, Faculdade de Ciências e de Tecnologia, Universidade de Coimbra, 3001-401 Coimbra, Portugal.
  • Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.

ORCID-Profile: Sérgio F Sousa, Flávia Sousa, Hélder A Santos

Förderung

  • HORIZON EUROPE European Innovation Council
  • Universitair Medisch Centrum Groningen
  • H2020 Marie Sklodowska-Curie Actions
  • Health-Holland

Zitieren

APA

Lopez-Parra, J. S., Hameedat, F., Sousa, S. F., Walenkamp, A. M. E., Sousa, F., & A Santos, H. (2026). Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01538

Vancouver

Lopez-Parra JS, Hameedat F, Sousa SF, Walenkamp AME, Sousa F, A Santos H. Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01538

BibTeX
@article{LopezParra2026,
  author = {Lopez-Parra, Johan Sebastian and Hameedat, Fatima and Sousa, Sérgio F and Walenkamp, Annemiek M E and Sousa, Flávia and A Santos, Hélder},
  title = {Identification of Subtype-Specific Vulnerabilities in Resistant Glioblastoma: A Computational Pipeline for Biomarkers and Drug Discovery},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01538}
}
Kostenlos starten →